Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific IgE (Protana).
- Sponsor
- Carsten Bindslev-Jensen
- Study ID
- NCT03964051
- Phase
- PHASE4
- Status
- Terminated
Conditions
- Food Allergy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Omalizumab Injection — DRUGOmalizumab 300 mg for subcutaneous injection
Study Details
Anaphylaxis elicited by accidental intake of the offending food constitutes a major health risk to the food allergic patient. Current advice for the food allergic patient is to avoid the offending food allergen and to carry an epinephrine autoinjector. However, novel treatments altering the clinical reactivity to the offending food thereby diminishing the risk of anaphylaxis are much needed. A correlation between the level of specific IgE in serum towards the offending food and the clinical sensitivity of the patient has been suggested. The clinical threshold for a food allergic reaction to occur is therefore hypothesized to increase by reducing the level of specific IgE to the relevant food allergen. Therapy with Omalizumab has proven efficacious in lowering the level of IgE in serum but a high pre-treatment level of total IgE in serum potentially hampers the efficacy in a number of patients, as seen especially in patients with concomitant atopic dermatitis. The aim of this study is to investigate if the combination of initial IgE specific immunoadsorption combined with subsequent treatment with Omalizumab will increase the clinical threshold to the culprit food and thus prevent medical emergencies (anaphylaxis) in patients with severe food allergy.
Key Dates
- Start date
- Jul 1, 2019
- Status verified
- Dec 2023
- Primary completion
- Dec 21, 2020
- Completion
- Dec 21, 2020
Study Design
- Enrollment
- 7 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Omalizumab 300 mg for s.c.injectionOmalizumab 300 mg steril solution in prefilled syringes are administrated every 2. week for 12 weeks
Primary Outcome Measure
Change in food challenge threshold (as measured in amount of food protein in milligrams tolerated by oral challenge) [ Time Frame: 18 weeks ]
Related Studies
- Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic DisordersRecruiting · Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio
- Molecular Basis of Food AllergyEnrolling By Invitation · Children's Hospital of Philadelphia · Philadelphia, Pennsylvania
- Natural History and Genetics of Food Allergy and Related ConditionsRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Prescreening Protocol to Enroll in Food Allergy Clinical Studies at a Single SiteRecruiting · Stanford University · Palo Alto, California